BR112018005163A2 - terapia de combinação de cenicriviroc para o tratamento de fibrose - Google Patents

terapia de combinação de cenicriviroc para o tratamento de fibrose

Info

Publication number
BR112018005163A2
BR112018005163A2 BR112018005163A BR112018005163A BR112018005163A2 BR 112018005163 A2 BR112018005163 A2 BR 112018005163A2 BR 112018005163 A BR112018005163 A BR 112018005163A BR 112018005163 A BR112018005163 A BR 112018005163A BR 112018005163 A2 BR112018005163 A2 BR 112018005163A2
Authority
BR
Brazil
Prior art keywords
cenicriviroc
ppar
cvc
agonist
fibrosis treatment
Prior art date
Application number
BR112018005163A
Other languages
English (en)
Inventor
Lefebvre Eric
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of BR112018005163A2 publication Critical patent/BR112018005163A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Abstract

cenicriviroc (cvc) é um antagonista oralmente ativo do ligante que se liga ao receptor cc-quimiocina tipo 5 (ccr5) e ao receptor cc-quimiocina tipo 2 (ccr2). cvc bloqueia a ligação de rantes, mip-1a, e mip-1ß a ccr5 e de mcp-1/ccl2 a ccr2. métodos de tratamento de fibrose e condições relacionadas que compreendem a coadministração de cvc com antagonistas de quimiocinas, agonistas de fxr, alta dose de vitamina e (> 400 iu/d), um agonista do receptor ativado por proliferador de peroxissoma alfa (ppar-a), agonista de ppar-¿ e/ou agonista do ppar-d são fornecidos neste documento.
BR112018005163A 2015-09-16 2016-03-16 terapia de combinação de cenicriviroc para o tratamento de fibrose BR112018005163A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219356P 2015-09-16 2015-09-16
PCT/US2016/022639 WO2017048322A1 (en) 2015-09-16 2016-03-16 Cenicriviroc combination therapy for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
BR112018005163A2 true BR112018005163A2 (pt) 2018-10-09

Family

ID=58289631

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005163A BR112018005163A2 (pt) 2015-09-16 2016-03-16 terapia de combinação de cenicriviroc para o tratamento de fibrose

Country Status (14)

Country Link
US (2) US20180360846A1 (pt)
EP (1) EP3349751A4 (pt)
JP (1) JP2018532720A (pt)
KR (1) KR20180088373A (pt)
CN (1) CN108289881A (pt)
AU (1) AU2016323468A1 (pt)
BR (1) BR112018005163A2 (pt)
CA (1) CA2998509A1 (pt)
HK (1) HK1258396A1 (pt)
IL (1) IL258002A (pt)
MX (1) MX2018003179A (pt)
RU (1) RU2018113437A (pt)
SG (1) SG10202002323UA (pt)
WO (1) WO2017048322A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
AU2015267148B2 (en) 2014-05-28 2021-07-29 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
WO2017192997A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
CN117229994A (zh) 2016-11-04 2023-12-15 儿童医院医学中心 肝类器官疾病模型以及其制备和使用方法
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
NZ753873A (en) 2016-12-05 2023-01-27 Children’S Hospital Medical Center Colonic organoids and methods of making and using same
MA47166A (fr) * 2016-12-28 2021-05-19 Modunex Bio Corp Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatique
US11590108B2 (en) * 2017-02-24 2023-02-28 Genfit Pharmaceutical compositions for combination therapy
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
CN109806386A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Fxr激动剂与glp-1类似物的药物组合物和用途
EP3768690A4 (en) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. CRYSTALLINE SHAPES AND METHOD FOR MAKING CRYSTALLINE SHAPES OF A COMPOUND
WO2020006199A2 (en) 2018-06-27 2020-01-02 The Regents Of The University Of California Methods and agents for modulating inflammation
CN113677336B (zh) * 2019-04-10 2024-04-30 基恩菲特公司 包含式(i)化合物和glp-1受体激动剂的组合疗法
CN110559297B (zh) * 2019-09-09 2023-03-17 中山大学 咪唑并吡啶类化合物在制备抗黄病毒属病毒感染试剂或药物中的应用
CN115667247B (zh) * 2020-05-22 2024-04-12 南京明德新药研发有限公司 吡啶类衍生物及其应用
CN114028377A (zh) * 2021-11-29 2022-02-11 中国农业大学 咖啡醇的医药新用途
WO2023133607A1 (en) * 2022-01-14 2023-07-20 Dimerix Bioscience Pty Ltd Compositions comprising a chemokine receptor pathway inhibitor
CN115414363B (zh) * 2022-10-08 2023-07-07 湖南师范大学 抗肝癌组合物和苯乙双胍在制备抗肝癌药物增敏剂的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032549A1 (en) * 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
CA2821985C (en) * 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
AU2014265327B2 (en) * 2013-05-15 2019-08-15 Tobira Therapeutics, Inc. Cenicriviroc compositions and methods of making and using the same
CA2931975A1 (en) * 2013-12-02 2015-06-11 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
WO2015143367A2 (en) * 2014-03-21 2015-09-24 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
US20170043021A1 (en) * 2014-04-25 2017-02-16 The Johns Hopkins University Compositions comprising cyclodextrin incorporated collagen matrices for use in biomedical applications
EP3191100A4 (en) * 2014-09-12 2018-05-30 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis

Also Published As

Publication number Publication date
HK1258396A1 (zh) 2019-11-08
CA2998509A1 (en) 2017-03-23
RU2018113437A3 (pt) 2019-10-17
US20180360846A1 (en) 2018-12-20
US20200268768A1 (en) 2020-08-27
KR20180088373A (ko) 2018-08-03
SG10202002323UA (en) 2020-05-28
MX2018003179A (es) 2018-08-21
IL258002A (en) 2018-05-31
EP3349751A1 (en) 2018-07-25
WO2017048322A1 (en) 2017-03-23
RU2018113437A (ru) 2019-10-17
CN108289881A (zh) 2018-07-17
EP3349751A4 (en) 2019-05-22
AU2016323468A1 (en) 2018-04-26
JP2018532720A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
BR112018005163A2 (pt) terapia de combinação de cenicriviroc para o tratamento de fibrose
BR112017004708A2 (pt) terapia de combinação de cenicriviroc para o tratamento de fibrose
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
BR112017024555A2 (pt) moduladores de ccr2
BR112017018715A2 (pt) agonista de receptor de angiotensina ii para tratar fibrose pulmonar
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
BR112018014675A2 (pt) novos derivados de cianoindolina substituída como inibidores de nik
MX2017008150A (es) Derivados de bencimidazol sulfonamidas como agonistas inversos del receptor gamma huerfano relacionado con el retinoide por gamma (t).
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
EA201692433A1 (ru) Соединения ppar для применения при лечении фиброзных заболеваний
CO2017008031A2 (es) Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
MY201535A (en) Therapeutic compounds
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
EP3632469A3 (en) Cyp2j2 antagonists in the treatment of pain
CO2022008012A2 (es) Antagonistas heterocíclicos de nmda
BR112018067923A2 (pt) métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112018073410A2 (pt) combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
CL2011001436A1 (es) Compuestos derivados de 4-[(2r)-4-terc-butilpiperazina-2-carbonil]-n-(4-cloro-3-fluorofenil)piperazina-1-carboxamida; antagonista del receptor crr2b; composicion farmaceutica; util en tratamiento de enfermedades inflamatorias y/o dolor neuropatico.
PH12021550671A1 (en) Prodrugs of cgrp antagonists
PE20170926A1 (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements